Abstract
Binding to the primary receptor, CD4, triggers conformational changes in the metastable HIV-1 envelope glycoprotein (Env) trimer ((gp120-gp41)3) that are important for virus entry into host cells. These changes include an 'opening' of the trimer, creation of a binding site for the CCR5 co-receptor and formation and/or exposure of a gp41 coiled coil. Here we identify a new compound, 18A (1), that specifically inhibits the entry of a wide range of HIV-1 isolates. 18A does not interfere with CD4 or CCR5 binding, but it inhibits the CD4-induced disruption of quaternary structures at the trimer apex and the exposure of the gp41 HR1 coiled coil. Analysis of HIV-1 variants with increased or reduced sensitivity to 18A suggests that the inhibitor can distinguish distinct conformational states of gp120 in the unliganded Env trimer. The broad-range activity and observed hypersensitivity of resistant mutants to antibody neutralization support further investigation of 18A.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
CD4 Antigens / chemistry
-
CD4 Antigens / genetics
-
CD4 Antigens / metabolism
-
Cell Line, Transformed
-
Dose-Response Relationship, Drug
-
Gene Expression
-
HIV Envelope Protein gp120 / chemistry*
-
HIV Envelope Protein gp120 / genetics
-
HIV Envelope Protein gp120 / metabolism
-
HIV Envelope Protein gp41 / chemistry*
-
HIV Envelope Protein gp41 / genetics
-
HIV Envelope Protein gp41 / metabolism
-
HIV Fusion Inhibitors / chemistry
-
HIV Fusion Inhibitors / pharmacology*
-
HIV-1 / drug effects*
-
HIV-1 / physiology
-
HeLa Cells
-
Humans
-
Protein Binding
-
Protein Multimerization
-
Protein Structure, Quaternary / drug effects*
-
Receptors, CCR5 / chemistry
-
Receptors, CCR5 / genetics
-
Receptors, CCR5 / metabolism
-
Recombinant Fusion Proteins / chemistry
-
Recombinant Fusion Proteins / genetics
-
Recombinant Fusion Proteins / metabolism
-
Semicarbazones / chemistry
-
Semicarbazones / pharmacology*
-
Thiadiazoles / chemistry
-
Thiadiazoles / pharmacology*
-
Viral Load / drug effects
-
Virus Internalization / drug effects*
Substances
-
1-(2,1,3-benzothiadiazol-4-yl)-3-((E)-(4-hydroxyphenyl)methyleneamino)urea
-
CCR5 protein, human
-
CD4 Antigens
-
HIV Envelope Protein gp120
-
HIV Envelope Protein gp41
-
HIV Fusion Inhibitors
-
Receptors, CCR5
-
Recombinant Fusion Proteins
-
Semicarbazones
-
Thiadiazoles
-
gp120 protein, Human immunodeficiency virus 1
-
gp41 protein, Human immunodeficiency virus 1
Associated data
-
PubChem-Substance/196409802
-
PubChem-Substance/196409803
-
PubChem-Substance/196409804
-
PubChem-Substance/196409805
-
PubChem-Substance/196409806
-
PubChem-Substance/196409807
-
PubChem-Substance/196409808
-
PubChem-Substance/196409809
-
PubChem-Substance/196409810
-
PubChem-Substance/196409811
-
PubChem-Substance/196409812
-
PubChem-Substance/196409813
-
PubChem-Substance/196409814
-
PubChem-Substance/196409815
-
PubChem-Substance/196409816
-
PubChem-Substance/196409817
-
PubChem-Substance/196409818
-
PubChem-Substance/196409819
-
PubChem-Substance/196409820
-
PubChem-Substance/196409821
-
PubChem-Substance/196409822
-
PubChem-Substance/196409823
-
PubChem-Substance/196409824
-
PubChem-Substance/196409825
-
PubChem-Substance/196409826
-
PubChem-Substance/196409827
-
PubChem-Substance/196409828
-
PubChem-Substance/196409829
-
PubChem-Substance/196409830
-
PubChem-Substance/196409831
-
PubChem-Substance/196409832
-
PubChem-Substance/196409833
-
PubChem-Substance/196409834